Compound Evidence File
#EC-2026-0662
Teriparatide
Filed under Peptides. The bureau holds 117 laboratory returns for this compound from 37 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
37 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 5 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| WuXi TIDESCASE #VI-2026-0335 | A | 5 | 10.0 | 9.9 | 10.0 | 11 Dec 2025 | 3 Apr 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Mar 2026 | 4 Jul 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 4 | 10.0 | 9.9 | 10.0 | 3 Jan 2026 | 23 Jun 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 3 | 10.0 | 10.0 | 10.0 | 11 Jun 2026 | 7 Jul 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 3 | 10.0 | 9.9 | 10.0 | 23 Mar 2026 | 7 Aug 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 2 | 10.0 | 10.0 | 10.0 | 14 Mar 2026 | 26 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 10.0 | 10.0 | 10.0 | 2 Feb 2026 | 25 May 2026 |
| SinoPepCASE #VI-2026-0387 | A | 2 | 10.0 | 10.0 | 10.0 | 6 Apr 2026 | 4 Aug 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 9.9 | 9.9 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Nov 2025 | 26 Apr 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 4 | 9.9 | 9.9 | 10.0 | 7 Feb 2026 | 16 Jul 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Nov 2025 | 17 Jun 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Apr 2026 | 14 Aug 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 4 | 9.9 | 9.9 | 10.0 | 4 Jun 2026 | 13 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 4 | 9.9 | 9.9 | 10.0 | 11 Feb 2026 | 22 Jul 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 9.9 | 5 Apr 2026 | 9 Aug 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 12 Mar 2026 | 28 May 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 3 | 9.9 | 9.9 | 10.0 | 6 Feb 2026 | 6 Jul 2026 |
| BachemCASE #VI-2026-0314 | A | 2 | 9.9 | 9.9 | 10.0 | 3 Nov 2025 | 1 May 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 24 Jun 2026 | 25 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Mar 2026 | 9 Jul 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 2 | 9.9 | 9.9 | 10.0 | 27 Apr 2026 | 8 Aug 2026 |
| Hunan Ruiwang Technology CenterCASE #VI-2026-0027 | X | 1 | 9.3 | 9.3 | 9.3 | 3 Jul 2025 | 3 Jul 2025 |
| Huaian Hanyou PeptideCASE #VI-2026-0297 | X | 1 | 9.2 | 9.2 | 9.2 | 3 Jun 2025 | 3 Jun 2025 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 9.0 | 8.9 | 9.1 | 24 May 2026 | 24 May 2026 |
| Bfflist AMOCASE #VI-2026-0678 | X | 3 | 8.8 | 8.0 | 10.0 | 28 Mar 2025 | 23 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 7 | 8.7 | 7.8 | 9.5 | 24 May 2026 | 24 May 2026 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 8 | 8.5 | 6.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 7 | 8.3 | 7.1 | 9.1 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 3 | 8.2 | 7.7 | 8.6 | 24 May 2026 | 24 May 2026 |
| Shandong Aishi BiotechnologyCASE #VI-2026-0308 | X | 3 | 8.1 | 6.1 | 9.5 | 13 Jun 2025 | 20 May 2026 |
| Shanghai Leader Peptide BiotechnologyCASE #VI-2026-0558 | X | 1 | 7.6 | 7.6 | 7.6 | 27 Feb 2025 | 27 Feb 2025 |
| Rayshine Peptide BiochemicalsCASE #VI-2026-0545 | X | 1 | 7.4 | 7.4 | 7.4 | 24 Apr 2025 | 24 Apr 2025 |
| LipeptidesCASE #VI-2026-0863 | X | 1 | 5.6 | 5.6 | 5.6 | 21 May 2025 | 21 May 2025 |
| Prime PeptidesCASE #VI-2026-0696 | X | 1 | 5.5 | 5.5 | 5.5 | 16 Mar 2025 | 16 Mar 2025 |
| Hangzhou Youngpeptide Biotechnology HYBCASE #VI-2026-0347 | X | 1 | 5.2 | 5.2 | 5.2 | 7 May 2025 | 7 May 2025 |
Open any subject to view the batch-level evidence for Teriparatide alone.